Heuron signs a solution supply contract with Singapore's Raffles Hospital

Jul. 2025

Accelerating the targeting of the Southeast Asian medical hub

Introducing dementia and Parkinson's disease solutions to a premium screening center




Heuron (CEO Shin Dong-hoon), a medical artificial intelligence (AI) company specializing in brain neurological disorders, recently announced that it has signed an AI solution supply contract with Singapore's Raffles Hospital.


Under this agreement, Heuron will introduce HeuronPD, an AI solution for the early diagnosis of Parkinson's disease, and HeuronAD, an AI solution to assist in the diagnosis of Alzheimer's disease, to the health screening center at Raffles Hospital.


HeuronPD is an MRI-based diagnostic solution for Parkinson's disease that provides results such as ▲automatic analysis of the nigrosome area, ▲analysis of the onset of Parkinson's disease, and ▲quantitative analysis of the volume of the nigrosome area. HeuronAD is an AI solution that precisely analyzes the structure of detailed brain regions through 3D MRI to determine the degree of brain atrophy compared to others of the same age.


Raffles Hospital is a top-tier private general hospital representing Singapore and the Southeast Asian region, boasting high authority by providing world-class medical services. In particular, it is active in introducing cutting-edge medical technology and has a high reputation as a key medical hub in Asia, visited not only by its own citizens but also by numerous overseas patients.


The decision by Raffles Hospital to adopt Heuron's AI solutions for the early detection and management of degenerative brain diseases is highly significant in that it recognizes Heuron's unrivaled technological prowess and clinical validity.


In particular, as the solution is being introduced to a premium health screening center with a high interest in preventive healthcare, Heuron's solution is expected to play a key role in improving patient prognosis through early diagnosis of diseases.


CEO Shin Dong-hoon said, "Through this introduction at Raffles Hospital, Heuron plans to expand its influence in Singapore and use this as a bridgehead to accelerate business expansion throughout Southeast Asia." He added, "We expect to expand our supply to major hospitals and screening centers in Singapore in the future and achieve significant sales growth through this."


Meanwhile, earlier this year, Heuron obtained a Class B rating from the Singapore Health Sciences Authority (HSA) for its Parkinson's disease solution.

TOP